New program is launched to address the ongoing Ebola crisis

By Shakespeare Pharma
In November 6, 2014

In Brussels today it was announced that the EFPIA, its specialised group Vaccines Europe and the Innovative Medicines Initiative (IMI) have responded to the ongoing Ebola crisis by launching a new program with a staggering budget of €280 million.

‘Ebola+’ aims to encourage collaboration between researchers and the pharmaceutical industry to address the current Ebola crisis and cover the future needs of haemorrhagic fevers.

The first Call for proposals will result in projects aimed at addressing the development, manufacture, transport, and storage of vaccines; ensuring compliance with vaccine regimens; and the development of rapid diagnostic tests. The first projects are expected to begin in early 2015 and further Calls for proposals will be initiated in the upcoming months.

Richard Bergstrom, Director General EFPIA made a statement to say “The pharmaceutical industry, represented by EFPIA, recognises its responsibility and value and is ready to play a vital role”, whilst The European Commissioner for Research, Science and Innovation, Carlos Moedas, said:

“The EU is determined to help find a solution to Ebola. We are putting our money where our mouth is and boosting EU research on Ebola with an additional €280 million. With this funding from Horizon 2020 and our industry partners, we are stepping up the development of new vaccines and medications to help save lives around the world.”

Meanwhile, Michel Goldman, IMI Executive Director commented:

“Today’s launch of IMI’s Ebola+ programme exemplifies IMI’s firm commitment to addressing major health challenges where there is an unmet medical need and where the impact on public health is high. I am confident that by bringing together a wide range of stakeholders in collaborative projects, IMI will make a tangible contribution to global efforts to tackle this terrible disease.”

Leave A Comment